{
"info": {
"nct_id": "NCT00017576",
"official_title": "Phase II Study of Calcitrol Enhanced Carboplatin in Hormone Refractory Prostate Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed adenocarcinoma of the prostate Stage IV Evidence of progression despite standard hormonal management including antiandrogen withdrawal, defined as 1 of the following: Development of new metastatic lesions Increase in cancer-related pain A 50% rise in prostate-specific antigen (PSA) levels confirmed by 2 measurements at least 2 weeks apart PSA at least 5 ng/mL Testosterone less than 50 ng/mL\n\nPATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 1.3 mg/dL Calcium no greater than 10.5 mg/dL Phosphorus no greater than 4.2 mg/dL No kidney stones within the past 5 years No history of cancer-related hypercalcemia Cardiovascular: No uncontrolled heart failure Other: No other malignancy within the past 5 years except nonmelanoma skin cancer No significant active medical illness that would preclude study Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 1 type of prior chemotherapy for prostate cancer No prior carboplatin or cisplatin for prostate cancer Endocrine therapy: See Disease Characteristics At least 4 weeks since prior flutamide or nilutamide (6 weeks for bicalutamide) Concurrent primary hormonal therapy allowed (e.g., gonadotropin-releasing hormone agonist or antagonist) Radiotherapy: At least 1 month since prior radiotherapy At least 2 months since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium Surgery: Concurrent orchiectomy allowed Other: At least 7 days since prior thiazide diuretic At least 30 days since prior investigational therapy No prior calcitriol for prostate cancer No concurrent magnesium-containing antacids, bile-resin binders, or calcium supplements"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 120 Years",
"criterions": [
{
"exact_snippets": "maximum age of 120 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 120,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed adenocarcinoma of the prostate Stage IV Evidence of progression despite standard hormonal management including antiandrogen withdrawal, defined as 1 of the following: Development of new metastatic lesions Increase in cancer-related pain A 50% rise in prostate-specific antigen (PSA) levels confirmed by 2 measurements at least 2 weeks apart PSA at least 5 ng/mL Testosterone less than 50 ng/mL",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of the prostate",
"criterion": "adenocarcinoma of the prostate",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "Stage IV",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IV"
}
]
},
{
"exact_snippets": "Evidence of progression despite standard hormonal management including antiandrogen withdrawal",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "hormonal management",
"expected_value": "standard hormonal management including antiandrogen withdrawal"
}
]
},
{
"exact_snippets": "Development of new metastatic lesions",
"criterion": "new metastatic lesions",
"requirements": [
{
"requirement_type": "development",
"expected_value": true
}
]
},
{
"exact_snippets": "Increase in cancer-related pain",
"criterion": "cancer-related pain",
"requirements": [
{
"requirement_type": "increase",
"expected_value": true
}
]
},
{
"exact_snippets": "A 50% rise in prostate-specific antigen (PSA) levels confirmed by 2 measurements at least 2 weeks apart",
"criterion": "prostate-specific antigen (PSA) levels",
"requirements": [
{
"requirement_type": "rise",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
},
{
"requirement_type": "confirmation",
"expected_value": "2 measurements at least 2 weeks apart"
}
]
},
{
"exact_snippets": "PSA at least 5 ng/mL",
"criterion": "prostate-specific antigen (PSA) level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "ng/mL"
}
}
]
},
{
"exact_snippets": "Testosterone less than 50 ng/mL",
"criterion": "testosterone level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "ng/mL"
}
}
]
}
]
},
{
"line": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 1.3 mg/dL Calcium no greater than 10.5 mg/dL Phosphorus no greater than 4.2 mg/dL No kidney stones within the past 5 years No history of cancer-related hypercalcemia Cardiovascular: No uncontrolled heart failure Other: No other malignancy within the past 5 years except nonmelanoma skin cancer No significant active medical illness that would preclude study Fertile patients must use effective contraception",
"criterions": [
{
"exact_snippets": "Age: 18 and over",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "Performance status: ECOG 0-1",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": [
"ECOG 0",
"ECOG 1"
]
}
]
},
{
"exact_snippets": "Life expectancy: At least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Hematopoietic: WBC at least 3,000/mm3",
"criterion": "WBC",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 3000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Neutrophil count at least 1,500/mm3",
"criterion": "neutrophil count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Platelet count at least 100,000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Hepatic: Bilirubin no greater than 2.0 mg/dL",
"criterion": "bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.0,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "Renal: Creatinine no greater than 1.3 mg/dL",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.3,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "Calcium no greater than 10.5 mg/dL",
"criterion": "calcium",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 10.5,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "Phosphorus no greater than 4.2 mg/dL",
"criterion": "phosphorus",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 4.2,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "No kidney stones within the past 5 years",
"criterion": "kidney stones",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "No history of cancer-related hypercalcemia",
"criterion": "cancer-related hypercalcemia",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "Cardiovascular: No uncontrolled heart failure",
"criterion": "uncontrolled heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other malignancy within the past 5 years except nonmelanoma skin cancer",
"criterion": "other malignancy",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "No significant active medical illness that would preclude study",
"criterion": "significant active medical illness",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Fertile patients must use effective contraception",
"criterion": "contraception",
"requirements": [
{
"requirement_type": "usage",
"expected_value": true
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No more than 1 type of prior chemotherapy for prostate cancer No prior carboplatin or cisplatin for prostate cancer Endocrine therapy: See Disease Characteristics At least 4 weeks since prior flutamide or nilutamide (6 weeks for bicalutamide) Concurrent primary hormonal therapy allowed (e.g., gonadotropin-releasing hormone agonist or antagonist) Radiotherapy: At least 1 month since prior radiotherapy At least 2 months since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium Surgery: Concurrent orchiectomy allowed Other: At least 7 days since prior thiazide diuretic At least 30 days since prior investigational therapy No prior calcitriol for prostate cancer No concurrent magnesium-containing antacids, bile-resin binders, or calcium supplements",
"criterions": [
{
"exact_snippets": "No more than 1 type of prior chemotherapy for prostate cancer",
"criterion": "prior chemotherapy for prostate cancer",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "type"
}
}
]
},
{
"exact_snippets": "No prior carboplatin or cisplatin for prostate cancer",
"criterion": "prior carboplatin or cisplatin for prostate cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "At least 4 weeks since prior flutamide or nilutamide",
"criterion": "time since prior flutamide or nilutamide",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "6 weeks for bicalutamide",
"criterion": "time since prior bicalutamide",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "Concurrent primary hormonal therapy allowed",
"criterion": "concurrent primary hormonal therapy",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"exact_snippets": "At least 1 month since prior radiotherapy",
"criterion": "time since prior radiotherapy",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "month"
}
}
]
},
{
"exact_snippets": "At least 2 months since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium",
"criterion": "time since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Concurrent orchiectomy allowed",
"criterion": "concurrent orchiectomy",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"exact_snippets": "At least 7 days since prior thiazide diuretic",
"criterion": "time since prior thiazide diuretic",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 7,
"unit": "days"
}
}
]
},
{
"exact_snippets": "At least 30 days since prior investigational therapy",
"criterion": "time since prior investigational therapy",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 30,
"unit": "days"
}
}
]
},
{
"exact_snippets": "No prior calcitriol for prostate cancer",
"criterion": "prior calcitriol for prostate cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No concurrent magnesium-containing antacids, bile-resin binders, or calcium supplements",
"criterion": "concurrent magnesium-containing antacids, bile-resin binders, or calcium supplements",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}